Novogen (KZIA) Competitors $7.94 -0.07 (-0.87%) Closing price 09/17/2025 03:59 PM EasternExtended Trading$7.84 -0.10 (-1.26%) As of 06:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KZIA vs. RNTX, KLTO, MAAQ, RVPH, KZR, CASI, DARE, SONN, AKTX, and TENXShould you be buying Novogen stock or one of its competitors? The main competitors of Novogen include Rein Therapeutics (RNTX), Klotho Neurosciences (KLTO), Mana Capital Acquisition (MAAQ), Reviva Pharmaceuticals (RVPH), Kezar Life Sciences (KZR), CASI Pharmaceuticals (CASI), Dare Bioscience (DARE), Sonnet BioTherapeutics (SONN), Akari Therapeutics (AKTX), and Tenax Therapeutics (TENX). These companies are all part of the "pharmaceutical products" industry. Novogen vs. Its Competitors Rein Therapeutics Klotho Neurosciences Mana Capital Acquisition Reviva Pharmaceuticals Kezar Life Sciences CASI Pharmaceuticals Dare Bioscience Sonnet BioTherapeutics Akari Therapeutics Tenax Therapeutics Rein Therapeutics (NASDAQ:RNTX) and Novogen (NASDAQ:KZIA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment. Does the media prefer RNTX or KZIA? In the previous week, Rein Therapeutics had 2 more articles in the media than Novogen. MarketBeat recorded 4 mentions for Rein Therapeutics and 2 mentions for Novogen. Novogen's average media sentiment score of 0.96 beat Rein Therapeutics' score of 0.88 indicating that Novogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rein Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Novogen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings and valuation, RNTX or KZIA? Novogen has higher revenue and earnings than Rein Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRein TherapeuticsN/AN/A-$62.88M-$2.69-0.43Novogen$1.51M5.31-$17.56MN/AN/A Is RNTX or KZIA more profitable? Novogen's return on equity of 0.00% beat Rein Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Rein TherapeuticsN/A -141.11% -33.83% Novogen N/A N/A N/A Do institutionals & insiders hold more shares of RNTX or KZIA? 90.9% of Rein Therapeutics shares are owned by institutional investors. Comparatively, 30.9% of Novogen shares are owned by institutional investors. 5.1% of Rein Therapeutics shares are owned by company insiders. Comparatively, 1.0% of Novogen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has more risk and volatility, RNTX or KZIA? Rein Therapeutics has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Comparatively, Novogen has a beta of 2.19, suggesting that its stock price is 119% more volatile than the S&P 500. Do analysts rate RNTX or KZIA? Novogen has a consensus target price of $14.00, suggesting a potential upside of 76.32%. Given Novogen's stronger consensus rating and higher probable upside, analysts clearly believe Novogen is more favorable than Rein Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rein Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Novogen 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 SummaryNovogen beats Rein Therapeutics on 10 of the 13 factors compared between the two stocks. Get Novogen News Delivered to You Automatically Sign up to receive the latest news and ratings for KZIA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KZIA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KZIA vs. The Competition Export to ExcelMetricNovogenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.07M$3.12B$5.74B$10.30BDividend YieldN/A2.37%5.86%4.62%P/E RatioN/A21.0376.8526.52Price / Sales5.31249.02453.0387.93Price / CashN/A45.4837.2260.63Price / Book-0.809.5613.686.31Net Income-$17.56M-$53.02M$3.29B$271.37M7 Day Performance-2.58%-1.58%-0.75%0.57%1 Month Performance7.01%2.82%3.84%6.20%1 Year Performance-53.29%9.34%82.85%28.33% Novogen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KZIANovogen3.7137 of 5 stars$7.94-0.9%$14.00+76.3%-50.4%$8.07M$1.51M0.0012RNTXRein Therapeutics0.8079 of 5 stars$1.33-0.7%N/AN/A$31.00MN/A-0.499News CoverageKLTOKlotho Neurosciences0.5472 of 5 stars$0.50-0.4%N/AN/A$30.61MN/A-1.11N/APositive NewsMAAQMana Capital AcquisitionN/A$3.71+0.6%N/A+1,334.2%$30.14MN/A0.001RVPHReviva Pharmaceuticals2.9171 of 5 stars$0.44-2.0%$5.20+1,087.2%-68.4%$29.78MN/A-0.675Analyst ForecastKZRKezar Life Sciences3.668 of 5 stars$4.03+0.4%$9.00+123.6%-35.0%$29.46M$7M-0.4260News CoverageCASICASI Pharmaceuticals3.808 of 5 stars$2.35-0.2%$4.00+70.6%-72.4%$29.03M$28.54M-0.82180DAREDare Bioscience2.5631 of 5 stars$2.13-0.2%$10.00+370.6%-36.7%$28.65M$10K-0.9930Short Interest ↓SONNSonnet BioTherapeutics2.8952 of 5 stars$3.99+21.3%$20.00+401.0%-7.2%$27.93M$20K0.0010Positive NewsGap UpAKTXAkari Therapeutics3.7668 of 5 stars$0.85+0.1%$3.30+287.8%-76.1%$27.76MN/A0.009News CoverageUpcoming EarningsGap DownTENXTenax Therapeutics2.3424 of 5 stars$5.98-1.1%$18.00+201.3%+65.8%$27.26MN/A-6.499 Related Companies and Tools Related Companies RNTX Alternatives KLTO Alternatives MAAQ Alternatives RVPH Alternatives KZR Alternatives CASI Alternatives DARE Alternatives SONN Alternatives AKTX Alternatives TENX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KZIA) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredReagan’s former tech advisor sharing bombshell announcementGeorge Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novogen Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Novogen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KZIA Stock Alerts